CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new inhibitors for the mTORC1 protein complex, which regulates cell growth and metabolism. By creating synthetic derivatives of malonyl-CoA, it seeks to provide more effective treatments for diseases linked to mTOR dysregulation.
The mTOR (mammalian/mechanistic Target of Rapamycin) kinase, as part of the mTORC1 and mTORC2 protein complexes, is the master controller of cellular and organismal physiology.
Dysregulation of mTORC1 activity is tightly linked to human disease and ageing.
Consequently, mTOR inhibitors have been tested in various clinical settings, however with little success and limited applicability so far, mainly due to low efficacy or adverse effects, thus highlighting the need for more potent and more speci…
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
